August 16, 2021 -- PerkinElmer has released four new test kits designed to help researchers better understand KRAS protein structures and mutations. The kits will enable cancer researchers to accelerate the identification and optimization of therapeutic leads, the company said.
The new kits expand PerkinElmer's existing portfolio of homogeneous time resolved fluorescence (HTRF) and AlphaLISA offerings, both of which are ready-to-use assays for KRAS/SOS1 inhibition analysis in a no-wash format. Each kit comes with recombinant proteins, detection reagents, and assay buffers, PerkinElmer said.
"KRAS mutations are present in approximately 25% of tumors, making them one of the most common gene mutations linked to cancer," said Alan Fletcher, PhD, senior vice president of life sciences and technology, in a company statement. "Because KRAS mutations are found in numerous types of cancer, from lung to colorectal to pancreatic cancers, it's a prime drug target."
The company also offers early-stage drug discovery services, with assays, cell lines, microplates, and plate readers, as well as later-stage research, with high-content screening, image analysis and management, and automated liquid handling.